MX352871B - Método para disminuir inmunogenicidad. - Google Patents

Método para disminuir inmunogenicidad.

Info

Publication number
MX352871B
MX352871B MX2015010691A MX2015010691A MX352871B MX 352871 B MX352871 B MX 352871B MX 2015010691 A MX2015010691 A MX 2015010691A MX 2015010691 A MX2015010691 A MX 2015010691A MX 352871 B MX352871 B MX 352871B
Authority
MX
Mexico
Prior art keywords
decreasing immunogenicity
immunogenicity
decreasing
disclosed
variable domains
Prior art date
Application number
MX2015010691A
Other languages
English (en)
Inventor
Borras Leonardo
Urech David
Gunde Tea
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of MX352871B publication Critical patent/MX352871B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo de cadena única (scFv), en donde la scFv comprende una cadena ligera variable que comprende una serina en la posición 101 (numeración AHo) y una cadena pesada variable que comprende Serina (S) en la posición de la cadena pesada de aminoácido 12, Treonina (T) en la posición de la cadena pesada de aminoácido 103, y Treonina (T) en la posición de la cadena pesada de aminoácido 144 (numeración AHo).
MX2015010691A 2009-12-23 2010-12-21 Método para disminuir inmunogenicidad. MX352871B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28944609P 2009-12-23 2009-12-23
PCT/CH2010/000326 WO2011075861A1 (en) 2009-12-23 2010-12-21 Method for decreasing immunogenicity

Publications (1)

Publication Number Publication Date
MX352871B true MX352871B (es) 2017-12-13

Family

ID=43733894

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012005345A MX2012005345A (es) 2009-12-23 2010-12-21 Metodo para disminuir inmunogenicidad.
MX2015010691A MX352871B (es) 2009-12-23 2010-12-21 Método para disminuir inmunogenicidad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012005345A MX2012005345A (es) 2009-12-23 2010-12-21 Metodo para disminuir inmunogenicidad.

Country Status (16)

Country Link
US (4) US8796425B2 (es)
EP (3) EP2516461A1 (es)
JP (6) JP5914353B2 (es)
KR (3) KR101758703B1 (es)
CN (2) CN109293768A (es)
AR (1) AR079700A1 (es)
AU (1) AU2010335950B2 (es)
BR (1) BR112012017051A2 (es)
CA (1) CA2777527C (es)
CL (1) CL2012001696A1 (es)
MX (2) MX2012005345A (es)
RU (1) RU2585534C2 (es)
TW (3) TWI633184B (es)
UY (2) UY39290A (es)
WO (1) WO2011075861A1 (es)
ZA (4) ZA201202299B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0914319B8 (pt) * 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
HUE032894T2 (hu) * 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CN109293768A (zh) * 2009-12-23 2019-02-01 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 减少免疫原性的方法
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
IL250396B (en) * 2011-06-23 2022-06-01 Ablynx Nv Techniques for predicting, detecting, and reducing A-specific protein interference in assays involving single immunoglobulin variable domains
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
HUE056738T2 (hu) * 2014-05-16 2022-03-28 Ablynx Nv Eljárás gyógyszer elleni antitestek, különösen kezelés kapcsán kialakuló gyógyszer elleni antitestek detektálására és/vagy mérésére
RS60717B1 (sr) 2014-05-16 2020-09-30 Ablynx Nv Varijabilni domeni imunoglobulina
EP3368569B1 (en) * 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
RS60823B1 (sr) 2015-12-04 2020-10-30 Boehringer Ingelheim Int Biparatopski polipeptidi koji antagonizuju wnt signalizaciju u tumorskim ćelijama
AR108975A1 (es) 2016-07-06 2018-10-17 Celgene Corp Anticuerpos con baja inmunogenicidad y sus usos
AR111840A1 (es) 2017-05-31 2019-08-21 Boehringer Ingelheim Int Polipéptidos que antagonizan la señalización wnt en células tumorales
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2023110190A1 (en) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
EP4273162A1 (en) * 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023214047A1 (en) 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4357778A1 (en) 2022-10-20 2024-04-24 Heraeus Medical GmbH Treatment of microbial infections diagnosed using the biomarker d-lactate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018792A1 (en) 1992-03-18 1993-09-30 Biomira Inc. Selective alteration of antibody immunogenicity
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
KR20030074839A (ko) * 2001-02-19 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
UA85058C2 (ru) * 2003-08-13 2008-12-25 Пфайзер Продактс Инк. Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir)
PT2164961E (pt) * 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Manipulação baseada em sequências e otimização de anticorpos de cadeia única
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
US8537790B2 (en) * 2008-03-10 2013-09-17 Motorola Mobility Llc Hierarchical pilot structure in wireless communication systems
KR101790567B1 (ko) * 2008-06-25 2017-10-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역결합제의 용해도 최적화
BRPI0914319B8 (pt) * 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CN109293768A (zh) * 2009-12-23 2019-02-01 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 减少免疫原性的方法

Also Published As

Publication number Publication date
ZA201402145B (en) 2018-05-30
TW201619383A (zh) 2016-06-01
JP2021153603A (ja) 2021-10-07
CN109293768A (zh) 2019-02-01
JP5914353B2 (ja) 2016-05-11
AR079700A1 (es) 2012-02-15
US20150080555A1 (en) 2015-03-19
KR20170036137A (ko) 2017-03-31
AU2010335950A1 (en) 2012-07-19
JP2019141071A (ja) 2019-08-29
UY39290A (es) 2021-07-30
EP3498731A1 (en) 2019-06-19
RU2585534C2 (ru) 2016-05-27
US8796425B2 (en) 2014-08-05
UY33154A (es) 2011-06-30
US9803027B2 (en) 2017-10-31
US20180016350A1 (en) 2018-01-18
TWI662128B (zh) 2019-06-11
CL2012001696A1 (es) 2013-03-08
EP2516461A1 (en) 2012-10-31
CA2777527C (en) 2020-06-23
WO2011075861A1 (en) 2011-06-30
US10781268B2 (en) 2020-09-22
TWI633184B (zh) 2018-08-21
JP2016094487A (ja) 2016-05-26
JP6815083B2 (ja) 2021-01-20
JP2013515460A (ja) 2013-05-09
KR101758703B1 (ko) 2017-07-18
CA2777527A1 (en) 2011-06-30
KR20120102061A (ko) 2012-09-17
AU2010335950B2 (en) 2014-08-21
TW201925228A (zh) 2019-07-01
ZA201202299B (en) 2014-06-25
BR112012017051A2 (pt) 2017-12-05
JP2017121254A (ja) 2017-07-13
ZA201706443B (en) 2020-12-23
RU2012130945A (ru) 2014-01-27
MX2012005345A (es) 2012-06-08
ZA202006532B (en) 2022-04-28
KR101721187B1 (ko) 2017-03-29
US20210214461A1 (en) 2021-07-15
US20110152505A1 (en) 2011-06-23
KR20170084357A (ko) 2017-07-19
JP2015131855A (ja) 2015-07-23
TW201125975A (en) 2011-08-01
CN102686608A (zh) 2012-09-19
EP4219545A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
MX352871B (es) Método para disminuir inmunogenicidad.
HK1219741A1 (zh) 結構域抗體的生產方法
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
IL217381A0 (en) Optimizing the production of antibodies
HUE051430T2 (hu) Eljárás variábilis domének elõállítására
GB2472482B (en) Contextual voice commands
IL200919A0 (en) Methods for generation of antibodies
EP2582778C0 (en) PROCESS FOR PRODUCTION OF METHANE FROM BIOMASS
PL2563739T3 (pl) Sposób wytwarzania cegieł przy zastosowaniu bakterii wytwarzającej enzym
AU2013207589A1 (en) Anti-Siglec-15 Antibody
NZ621170A (en) Anti-human cd52 immunoglobulins
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
MY163339A (en) A method of producing ingenol-3-angelate
PL2553082T3 (pl) Sposób i urządzenie do wytwarzania biogazu
PL2632946T3 (pl) Sposób wytwarzania pojedynczych domen zmiennych immunoglobulin
SG10201505561TA (en) A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
IL205051A (en) Method for producing antibodies
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
EP2406285A4 (en) Generation, expression and characterization of the humanized monoclonal antibody K33N
WO2010109185A3 (en) Process for the preparation of doxazosin and salts thereof
PL2526087T3 (pl) Sposób wytwarzania wodoronadtlenku alkilu
GB201020045D0 (en) Method for the treatment of biogas
MX2013002395A (es) Procedimiento de preparacion de ditiin-tetracarboximidas.
GB2480419B (en) Method for the manufacture of ethanol